Top Markets
Coin of the day
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
株式のランク #40876
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
株価
$0.0127
最終同期: 2026-08-12
時価総額
$66.48K
変化(1日)
-2.31%
変化(1年)
-67.44%
US
取引 Vincerx Pharma, Inc. (VINC)

カテゴリー

Vincerx Pharma, Inc.(VINC)の配当履歴
Vincerx Pharma, Inc.(証券コード:VINC)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのVincerx Pharma, Inc.(VINC)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴